

NAME OF ASSESSEE	: DR NRKBIOTECH PRIVATE LIMITED		
PAN	: AACCD2775Q		
OFFICE ADDRESS	: H.NO.502, SURAKSHA SOVENIR, WHITE FIELDS, KOTHAGUDA, HITECH CITY HYDERABAD-32, TELANGANA-500084		
STATUS	: PUB NOT INT (PRIVATE LTD)	ASSESSMENT YEAR	: 2024 - 2025
WARD NO	: WARD 17(1), HYDERABAD/	FINANCIAL YEAR	: 2023 - 2024
D.O.I.	: 23/12/2004		
EMAIL ADDRESS	: nnagapooja@gmail.com		
NAME OF BANK	: STATE BANK OF INDIA		
IFSC CODE	: SBIN0020458		
ADDRESS	: JUBILEE HILLS, HYDERABAD		
ACCOUNT NO.	: 62062629504		
RETURN	: ORIGINAL		
IMPORT DATE	: AIS : 25-10-2024 03:14 PM	TIS : 25-10-2024 03:14 PM	26AS : 25-
	10-2024 03:14 PM		
COMPUTATION DATE	: 07-11-2024 12:04 PM		

COMPUTATION OF TOTAL INCOME

PROFITS AND GAINS FROM BUSINESS AND PROFESSION

0

DR NRK BIOTECH PVT LTD

PROFIT BEFORE TAX AS PER PROFIT AND LOSS ACCOUNT	-7679767
ADD :	

DEPRECIATION DISALLOWED	350049	
DISALLOWED U/S 37	274670	624719
	<u>274670</u>	<u>624719</u>
		-7055048

LESS :		
INTEREST INCOME ON FD	476075	
INTEREST ON INCOME TAX REFUND	2954	
ALLOWED DEPRECIATION	567423	-1046452
	<u>567423</u>	<u>-1046452</u>
		<u>-8101500</u>

OUT OF LOSS OF RS. 8101500, UNABSORBED DEPRECIATION IS
RS. 567423 & BUSINESS LOSS IS RS. 7534077

CAPITAL GAINS

SHORT TERM CAPITAL GAIN ON LISTED SECURITIES (STT PAID)	144190	144190
--	--------	--------

INCOME FROM OTHER SOURCES

INTEREST ON BANK FD		479029
INTEREST ON INCOME TAX REFUND	476075	
TOTAL	2954	
	<u>476075</u>	
	<u>2954</u>	<u>479029</u>

INTER-HEAD ADJUSTMENT OF LOSSES U/S 71

BUSINESS LOSS SET OFF FROM INCOME FROM OTHER SOURCES	-479029
---	---------

BUSINESS LOSS SET OFF FROM STCG @ 15%	-144190
---------------------------------------	---------

CURRENT YEAR LOSSES CARRIED FORWARD

BUSINESS LOSS OF Rs. 6910858	
UNABSORBED DEPRECIATION OF Rs. 567423	

GROSS TOTAL INCOME

TOTAL INCOME	<u>NIL</u>
	<u>NIL</u>

COMPUTATION OF TAX ON TOTAL INCOME

TAX ON RS. NIL (AS PER NORMAL PROVISIONS)	<u>NIL</u>
---	------------

CALCULATION OF BOOK PROFIT U/S 115JB

NET PROFIT AS SHOWN IN THE PROFIT AND LOSS ACCOUNT	<u>-7684687</u>
--	-----------------

LESS TAX DEDUCTED AT SOURCE

SECTION 194A: OTHER INTEREST

47606

47606

-47606

REFUNDABLE

TAX REFUNDABLE ROUNDED OFF U/S 288B

(47606)

(47610)

Information regarding Turnover/Gross Receipt Reported for GST

GSTR No.	36AACCD2775Q1Z3
Amount of turnover/Gross receipt as per the GST return filed	6846

FIXED ASSETS

Block	Rate	WDV as on 01/04/2023	Addition		Deduction	Total	Depreciation for the Year	WDV as on 31/03/2024
			More than 180 Days	Less than 180 Days				
		Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
BUILDING	10.00%	47,48,735.00	0.00	0.00	0.00	47,48,735.00	4,74,874.00	42,73,861.00
MACHINERY AND PLANT	15.00%	7,35,364.00	1,91,817.00	0.00	3,90,000.00	5,37,181.00	80,577.00	4,56,604.00
MACHINERY AND PLANT	40.00%	0.00	29,931.00	0.00	0.00	29,931.00	11,972.00	17,959.00
Total		54,84,099.00	2,21,748.00	0.00	3,90,000.00	53,15,847.00	5,67,423.00	47,48,424.00

LOSSES TABLE

A.Y.	HEAD	LOSSES		
		BROUGHT FORWARD	SET-OFF	CARRIED FORWARD
2020-21	Ordinary Business	9068419	-	9068419
2021-22	Ordinary Business	4076139	-	4076139
2022-23	Ordinary Business	1833437	-	1833437
2022-23	Unabsorbed Depreciation	619241	-	619241
2023-24	Ordinary Business	4669612	-	4669612
2023-24	Unabsorbed Depreciation	657407	-	657407
2024-25	Ordinary Business	-	-	6910858
2024-25	Unabsorbed Depreciation	-	-	567423

DISALLOWED U/S 37

Sr. No.	Particulars	Amount
1	GST LATE FEES	
2	INTEREST ON TDS	680
3	LOSS ON SALE OF CAR	50610
	Total	223380
		274670.00

STATEMENT OF SHORT TERM CAPITAL GAIN ON LISTED SECURITIES / UNITS (STT PAID)

Name of Company	Date of Purchase/Y ear	Date of Sale/Year	Sales Price	Purchase Cost	Transfer Expenses	Amount received u/s 94(7) or 94(8)	Capital Gain
ADITYA BIRLA SUNLIFE MUTUAL FUND	29/12/2022	17/08/2023	3244190.00	3100000.00	0.00	0.00	144190.00
Total			3244190.00	3100000.00	0.00	0.00	144190.00

Schedule-SH1 [SHAREHOLDING OF UNLISTED COMPANY]**1. Details of shareholding at the end of the previous year**

Sr.	Name of the	Resident	Type of	Others	PAN	AADHAAR	Date of	Number	Face	Issue	Amount
-----	-------------	----------	---------	--------	-----	---------	---------	--------	------	-------	--------

No.	shareholder	ial status in India	share				allotmen t	of shares held	value per share	Price per share	received
1	B ANAND KUMAR	Resident	Equity Shares		AENPB52 88E		03/07/2 008	241100	10	10	312500
2	JVRX ASSET MANAGEMENT PVT LTD	Resident	Equity Shares		AAECU98 13D		03/07/2 008	361650	10	10	156250
3	K VENKATA NAGABHUSH NAM	Resident	Equity Shares		GBQPK99 41B		03/07/2 008	241100	10	10	312500
4	K VENKATA NARSIMHA MURTY	Resident	Equity Shares		AHPPK99 98K		03/07/2 008	241100	10	10	312500
5	K VIJAY BHASKAR	Resident	Equity Shares		AHSPK37 85B		03/07/2 008	241100	10	10	312500
6	MODI PROPERTIES PVT LTD	Resident	Equity Shares		AABCM4 761E		03/07/2 008	602750	10	10	468750
7	N KIRAN KUMAR	Resident	Equity Shares		ABVPN12 78M		03/07/2 008	241100	10	10	312500
8	N KRISHNA VENI	Resident	Equity Shares		AIZPN17 55E		03/07/2 008	241100	10	10	312500
	Total							2411000 .00			250000 0.00

Schedule-AL1 [Assets and liabilities as at the end of the year]

B. Details of land or building or both not being in the nature of residential house

Sr. No.	Address	Pin code	Date of acquisition	Cost of acquisition	Purpose for which used
1	PLOT NO 11, ADMEASURING 11 471 SQ. YARDS, IN SHAPOORJI PALLONJI BIO TECH PARK, PHA SE 1, HYDERABAD, RR DIST	500038	15/04/2005	15842501	Own Office
	Total			15842501	

G. Details of Loans & Advances to any other concern (If money lending is not assessee's substantial business)

Sr. No.	Name of the person	PAN	Opening balance	Amount received	Amount paid	Interest debited, if any	Closing balance	Rate of interest (%)
1	SUP JOHNSON LIFTS PRIVATE LIMITED	AAACJ0838 Q	921000	2993250	3914250	0	1842000	0.00
2	SUP-KAVERI TIMBER DEPOT	AAFFK7078 K	3408	0	0	0	3408	0.00
3	SUP-PIRGALS HOUSE OF ELECTRONICS & HOMES APPLIANCES	ADYPP7519 G	37328	35500	35500	0	37328	0.00
4	SUP-S A SPORTS	AAGFS2959 C	84000	0	0	0	84000	0.00
5	SUP-SFS HARDWARE	BJJPG3515K	57802	751	0	0	57051	0.00
6	SUP-SHUBHAM ENTERPRISES	AELFS6374J	405	12685	12280	0	0	0.00
7	CONT-CHIRIPURAPU JOHN	COHPC9176 C	1566	240562	238996	0	0	0.00
8	CONT-KOTTE KASHANNA	CFAPK5353 R	3334705	12805686	9470981	0	0	0.00
9	CONT O VENKANNA	AASPO7141 C	12720	12720	0	0	0	0.00
10	OPEN CARD - GUNDA RAHUL	CPIPG5368 C	2657	18089	15432	0	0	0.00
11	OPEN CARD - MALLA REDDY	AMTPM952 4E	120	4220	5430	0	1330	0.00
12	LOAN-MAHESH RAMULU ESKILLA	AASPE2626 C	11000	11000	0	0	0	0.00
13	MODI CONSTRUCTIONS &	ABJFM5257	7202896	7188318	2010000	0	2024578	0.00

14	REALTORS LLP OTHLOAN-AL NAGARAJU	F ABGPN3651 D	172683	345366	172683	0	0	0.00
15	TCS-SRI GANESH TRADERS	ADWFS923 1N	6827	0	0	0	6827	0.00
16	TCS-ULTRA TECH CEMENT LIMITED	AAACL6442 L	16811	16811	0	0	0	0.00
17	SP-MN SCIENCE AND TECHNOLOGY PARK PVT LTD	AAFCS6041 M	1731718	443039	405690	0	1694369	0.00
18	SP-PARIVARTAN CONCEPTS	ACZPJ3438L	1981	18181	16200	0	0	0.00
19	SP - RKS MOTOR PVT LTD	AAACR9764 P	191817	191817	0	0	0	0.00
20	SP-SUMMIT BUILDERS	AAYFS2757 C	100795	347154	246359	0	0	0.00
21	SP-T.SUNIL SINGH	AVTPS1690 L	7800	19800	12000	0	0	0.00
22	SUP-PRİYANKA PRINTERS	AROPK5593 K	599	1960	1950	0	589	0.00
23	CONT-SAKEENA	MJQPS5287 L	0	37941	43823	0	5882	0.00
24	CONT-BANITADAS	GHVPD1030 H	0	40309	67826	0	27517	0.00
25	CONT-MD JAMSHED AHMED	AVKPA8896 R	0	61000	66000	0	5000	0.00
26	ECARD-K SUNEEL KUMAR	BDCPK3006 J	0	0	325	0	325	0.00
27	ECARD-SHRAVYA SUDA	OPUPS8859 L	0	215451	220916	0	5465	0.00
28	OPEN CARD-DR.NRK BIOTECH PRIVATE LIMITED	COHPC9176 C	4502	4502	0	0	0	0.00
29	OPEN CARD-P RAGHU	COHPC9176 C	0	11603	11603	0	0	0.00
30	OPEN CARD-SHIVA SHANKAR	BTMPS9528 R	0	4400	4400	0	0	0.00
31	EMP-BALA MURALI KRISHNA	COHPC9176 C	11125	148635	137510	0	0	0.00
32	EMP-KATIKALA VINAY KUMAR	COHPC9176 C	0	97072	97072	0	0	0.00
33	EMP-NETHIKAR RAM KISHNAN	ABRPN9792 N	0	632270	632270	0	0	0.00
34	SP-ARENA CONSULTANTS	AHZPS4818 C	0	115196	659796	0	544600	0.00
35	SP-ASHISH AGARWAL HUF	COHPC9176 C	0	23400	23400	0	0	0.00
36	SP-INDRA REDDY	BUEPG0916 J	0	38400	38400	0	0	0.00
37	SP-KORUKONDA BHATTAR SRIVATHSA	AERPB5245 B	0	0	125000	0	125000	0.00
38	SP-KULKARNI CONSULTANTS	ADOPR1855 P	0	81000	81000	0	0	0.00
39	SP-MALVE SACHIN DURGADAS	AATPM620 5C	0	150000	150000	0	0	0.00
40	SP-S V ELECTRICALS	AOAPK9950 M	0	60000	129000	0	69000	0.00
41	SUNRISE ENTERPRISES	BBDPK9097 E	0	0	6000	0	6000	0.00
42	SUP -ADROIT TECHNICAL SERVICES	AACCD2775 Q	0	0	194700	0	194700	0.00
43	SUP-GP BUILDCON MATERIALS	AIZPG4074 G	0	11505	20391	0	8886	0.00
44	SUP-MAA SAI SEATINGS	COHPC9176 C	0	21240	22990	0	1750	0.00
45	SUP-SHAH ENTERPRISES	COHPC9176 C	0	0	1480	0	1480	0.00
46	SUP-SHAIK AFZAL	COHPC9176 C	0	0	55000	0	55000	0.00

47	SUP-SHWETA COMPUTERS & PERIPHERALS	AAVFS5784 P	0	0	1200	0	1200	0.00
48	SUP-SRI GANESH TRADERS	ADWFS923 1N	0	491347	491347	0	0	0.00
	Total		13916265	26952180	19839200	0	6803285	

H. Details of motor vehicle, aircraft, yacht or other mode of transport

Sr. No.	Particulars of asset	Others	Registration number of vehicle	Cost of acquisition	Date of acquisition	Purpose for which used
1	Others	MARUTI ALTO	TS08HV1024	439693	25/10/2021	Own Business Use
	Total			439693		

I. Details of liabilities (Details of loans, deposits and advances taken from a person other than financial institution)

Sr. No.	Name of the person	PAN	Opening balance	Amount received	Amount paid	Interest credited, if any	Closing balance	Rate of interest (%)
1	B ANAND KUMAR	AENPB5288E	26230304	0	3105304	0	2312500	0.00
2	K VENKATA NAGA BHUSHNAM	GBQPK9941B	19125000	4000000	0	0	2312500	0.00
3	K VENKATA NARSIMHA MURTHY	AHPPK9998K	21625000	1500000	0	0	2312500	0.00
4	N KIRAN KUMAR	ABVPN1278M	21125000	2000000	0	0	2312500	0.00
5	N KRISHNA VENI	AIZPN1755E	10625000	7000000	0	0	17625000	0.00
6	K VIJAY BHASKAR	AHSPK3785B	22125099	1000000	0	0	23125099	0.00
7	MODI PROPERTIES PVT. LTD.	AABCM4761E	32081257	28497000	9336014	0	51242243	0.00
8	JVRX ASSET MANAGEMENT PVT. LTD.	AAECJ9813D	9592187	2411000	5352131	0	6651056	0.00
	Total		162528847	46408000	17793449	0	107893398	

Details of Turnover as per GSTR-3B (As per AIS)

Sr. No.	GSTIN	ARN	Date of filing	Return Period	Taxable Turnover	Total Turnover
1	36AACCD2775Q1Z3	126231015395757		MAR-2024	0.00	0.00
2	36AACCD2775Q1Z3	126230922982646		FEB-2024	0.00	0.00
3	36AACCD2775Q1Z3	126230828936836		JAN-2024	0.00	0.00
4	36AACCD2775Q1Z3	126230726202958		DEC-2023	0.00	0.00
5	36AACCD2775Q1Z3	126230627453226		NOV-2023	0.00	0.00
6	36AACCD2775Q1Z3	126230536963553		OCT-2023	0.00	0.00
7	36AACCD2775Q1Z3	126230445143310		SEP-2023	0.00	0.00
8	36AACCD2775Q1Z3	126230351006582		AUG-2023	0.00	0.00
9	36AACCD2775Q1Z3	126230259390892		JUL-2023	0.00	0.00
10	36AACCD2775Q1Z3	126230164867536		JUN-2023	0.00	0.00
11	36AACCD2775Q1Z3	126230084837374		MAY-2023	0.00	6846.00
12	36AACCD2775Q1Z3	126230005675993		APR-2023	0.00	0.00
	Total				0.00	6846.00

Details of Taxpayer Information Summary

Details of Taxpayer Information Summary									
S. N.	Information Category	Income Head	Section	Processed Value	Derived Value	As per Computation/ ITR	Difference	As per 26AS	Difference
	(1)	(2)	(3)	(4)	(5)	(6)	(7)=(5)-(6)	(8)	(9)=(8)-(6)
1	Interest from deposit	Other Source	194A	476075.00	476075.00	476075.00			
2	Sale of securities and units of mutual fund	Capital Gain		3244190.00	3244190.00	3244190.00	Nil	476075.00	Nil
3	Business receipts	Business		41300.00	41300.00	0.00	41300.00	0.00	Nil
4	GST turnover	Profit & Loss A/c		6846.00	6846.00	0.00	6846.00	0.00	Nil
5	GST purchases	Profit & Loss A/c		40178017.00	40178017.00	0.00	40178017.00		

6	Purchase of time deposits			42000000.00	42000000.00				
7	Purchase of securities and units of mutual funds			6443868.00	6443868.00				

SOHAM MODI

DR. N.R.K. BIO-TECH PRIVATE LIMITED
BALANCE SHEET AS AT MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)


Particulars	Notes	As at March 31st, 2024	As at March 31st, 2023
Equity and Liabilities			
Shareholders' Funds			
Share Capital	3	2,41,100	1,92,880
Reserves and Surplus	4	(2,95,359)	(2,18,515)
		(54,259)	(25,635)
Non-Current Liabilities			
Long-term Borrowings	5A	33,04,588	24,79,738
Current Liabilities			
Trade Payables	6	1,42,178	1,25,184
Short Term Borrowings	5B	76,050	-
Other Current Liabilities	7	50,578	4,965
Short Term Provision	8	369	315
Total		35,19,504	25,84,567
Assets			
Non-Current Assets			
Property, Plant & Equipment			
-Tangible Assets	9A	2,08,093	2,15,509
-Capital Work in Progress	9B	28,55,307	18,60,125
		30,63,400	20,75,634
Deferred Tax Asset (Net)	10	35,795	35,844
Current Assets			
Cash and Cash Equivalents	11	8,613	56,660
Loans & Advances	12	1,14,815	1,98,458
Other Current Assets	13	2,96,880	2,17,970
Total		35,19,504	25,84,567

Significant Accounting Policies and Notes to Accounts

The notes referred to above form an integral part of financial statements.

1 & 2

As per our report of even date
for **Laxminiwas & Co.**
Chartered Accountants
Firm Registration No. 011168S



Vijay Singh

Partner

Membership No. 221671

UDIN: 242216T1BKBMQZ7852

Place : Hyderabad

Date : 3rd September, 2024.

For and on behalf of directors of
Dr. N.R.K. Bio-Tech Private Limited
CIN: U45100TG2004PTC044950



Soham Satish Modi

Director

DIN: 00522546



Anand Kumar Bhashyakarla

Director

DIN: 07739186


DR. N.R.K. BIO-TECH PRIVATE LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)

Particulars	Notes	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Revenue			
Revenue from Operations	14	-	347
Other Income	15	5,052	5,050
Total income		5,052	5,396
Expenditure			
Purchase of stock-in-trade		-	-
Change in Inventories of finished goods, work in process and stock in trade		-	-
Employee Benefit Expenses	16	7,350	5,858
Depreciation and Amortisation	8A & 9A	3,500	6,705
Finance Costs	17	28	25
Other Administrative Expenses	18	70,971	46,843
Total expenses		81,850	59,430
Loss before tax		(76,798)	(54,034)
Tax Expense:			
-Current Tax		49	565
-Income Tax relating to previous years		-	-
-Deferred Tax expense/(income)		49	565
Loss for the year		(76,847)	(54,598)
Earnings Per Share (EPS)			
Basic		(0.03)	(0.22)
Diluted		(0.04)	(0.03)


Significant Accounting Policies and Notes to Accounts 1 & 2
The notes referred to above form an integral part of financial statements.

As per our report of even date
for **Laxminiwas & Co.**
Chartered Accountants
Firm Registration No. 011168S


For and on behalf of directors of
Dr. N.R.K. Bio-Tech Private Limited
CIN: U45100TG2004PTC044950



Vijay Singh
Partner
Membership No. 221671
UDIN: 24221671BKBMQZ7852



Soham Satish Modi
Director
DIN: 00522546



Anand Kumar Bhashyakarla
Director
DIN: 07739186

Place : Hyderabad
Date : 03rd September, 2024

DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)

1. (A) CORPORATE INFORMATION

Dr. N.R.K. Bio-Tech Private Limited ("The Company") is a private limited company domiciled in India and incorporated under the provisions of Companies Act, 2013. The Company was incorporated on 23rd December 2004 and the company is engaged in manufacturing pharmaceuticals, medicinal chemicals and botanical products. Its registered office and Principal place of business is situated at TSHC Industrial Development Area, Plot no.11, S no. 230 to 243, Turkapally, Medchal-Malkajgiri Dist, Hyderabad, Telangana, India, 500078

1. (B) SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation:

a. The financial statements of the company have been prepared and presented under the historical cost convention, on the accrual and going concern basis of accounting in accordance with the accounting principles generally accepted in India ("Indian GAAP") and comply with the Accounting standards prescribed in the Companies (Accounting Standards) Rules, 2006 which continue to apply under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 7 of the Companies (Accounts) Rules, 2014.

b. All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division-I) to the Companies Act, 2013. Based on the nature of products dealt with and services rendered and the time between the acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current - non-current classification of assets and liabilities.

c. Rounding of amounts: All amount disclosed in these standalone financial statements and notes have been rounded off in Rs. Hundreds as per the requirement of Schedule III, unless otherwise stated.

Basis of Accounting:

These standalone financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013.

Use of Estimates:

The preparation of financial statements in conformity with Indian GAAP requires judgments, estimates and assumptions to be made that affect the reported amount of assets and liabilities, disclosure of contingent liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known/materialized.

Current/ Non-Current Classification:

All assets and liabilities have been classified as current or noncurrent as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. Based on the nature of products and the time between acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current/non-current classification of assets and liabilities.

Revenue Recognition:

Revenue is measured at fair value of the consideration received or receivable. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefit will flow to the company and specific criteria have been met for each of the companies activities.

Revenue from sale of services is recognised on transfer of all significant risks and rewards of ownership on completion of service. The amount recognised as revenue is exclusive of taxes

Interest income is recognised on the time proportion basis

Cash and cash equivalents:

Cash and cash equivalents include cash in hand, demand deposits with banks, other short-term highly liquid investments with original maturities of three months or less.

Property Plant and Equipment and Intangible Assets
Tangible Assets:

Tangible Assets, capital work in progress are stated at cost net of recoverable taxes, trade discounts and rebates and include amounts added on revaluation, less accumulated depreciation and impairment loss, if any. The cost of tangible assets comprises its purchase price, borrowing cost and any cost directly attributable to bringing the asset to its working condition for its intended use, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the assets. Subsequent expenditures related to an item of tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance. Projects under which assets are not ready for their intended use are shown as Capital Work-in-Progress.

Intangible Assets:

An intangible asset is recognized when it is probable that the future economic benefits attributable to the asset will flow to the enterprise and where its cost can be reliably measured. Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortization/depletion and impairment loss, if any. The cost comprises purchase price, borrowing costs, and any cost directly attributable to bringing the asset to its working condition for the intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets. Subsequent expenditure relating to intangible assets is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

Depreciation

Depreciation on Property, Plant and equipment is provided on written down value method in accordance with the rates and in the manner provided in the schedule II to the Companies Act, 2013. Depreciation on addition to tangible assets is provided on pro-rata basis from the date the assets are ready for intended use. Depreciation on sale/discard of tangible assets is provided for up-to the date of sale, deduction or discard of tangible assets as the case may be. The Company has adopted Schedule II to the Companies Act, 2013 which requires identification and determination of separate useful life for each major component of the property, plant and equipment, if they have useful life that is materially different from that of the remaining asset.

Impairment

The Company assesses at each balance sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the company estimates the recoverable amount of the asset.

The recoverable amount of an asset is the greater of its value in use and its net selling price. If such recoverable amount of the assets is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the statement of profit and loss. If at the balance sheet date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of amortized historical cost.

Investments

Investments that are readily realizable and are intended to be held for not more than one year from the date, on which such investments are made, are classified as current investments. All other investments are classified as long-term investments.



DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024

On initial recognition, all investments are measured at cost. The cost comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties. If an investment is acquired, or partly acquired, by the issue of shares or other securities, the acquisition cost is the fair value of the securities issued. If an investment is acquired in exchange for another asset, the acquisition is determined by reference to the fair value of the asset given up or by reference to the fair value of the investment acquired, whichever is more clearly evident.

Current investments are carried at cost or fair value, whichever is lower. Long-term investments are carried at cost. However, provision for diminution is made to recognize a decline, other than temporary, in the value of the investments. Such reduction if any is determined and made for each investment individually. On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the Statement of Profit and Loss.

Inventories

Inventories are stated at lower of cost and net realizable value. However, these items are considered to be realizable at replacement cost if the finished goods, in which they will be used, are expected to be sold below cost. Cost includes purchase price, (excluding those subsequently recoverable by the enterprise from the concerned revenue authorities), freight inwards and other expenditure incurred in bringing such inventories to their present location and condition. Cost is determined on the weighted average basis. The cost of raw materials, stores and spares and other consumables comprises cost of material and includes all applicable costs incurred in bringing goods to their present location and condition.

Work in progress and manufactured finished goods are valued at the lower of cost and net realizable value. Cost of work in progress and manufactured finished goods is determined on the weighted average basis and comprises direct material, Cost of conversion and other costs incurred in bringing these inventories to their present location and condition. Cost of traded goods is determined on a weighted average basis.

Provision of obsolescence on inventories is considered on the basis of management's estimate based on demand and market of the inventories.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale. The comparison of cost and net realizable value is made on item by item basis.

Borrowing costs

Borrowing cost includes interest, amortization of ancillary costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs that are directly attributable to the acquisition, construction or production of an asset that takes a substantial period of time to get ready for its intended use or sale are capitalized until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized as expenditure in the period in which they are incurred.

Provisions, Contingent Liabilities and Contingent Assets

Provision is recognized in the accounts when there is a present obligation as a result of past event(s) and it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

The company has capital commitments as mentioned below:

(A) Capital commitment:-

Particulars	Year Ended March 31st, 2024
Estimated amount of construction remaining to be executed	22,00,000
Loan repayment to Aditya Birla Finance Limited	15,00,000
Total Commitment	37,00,000

Project Construction estimated to be completed by 31st December, 2025.

Employee Benefits:

Defined Contribution Plan:

Contribution as per Employee's Provident Funds and Miscellaneous Provisions Act, 1952 towards Provident Fund and Family Pension Fund are provided for and payments in respect thereof are made to the relevant authorities on actual basis.

Taxation

Current Tax

Tax expense comprises of current tax (i.e. amount of tax for the period is determined in accordance with the Income Tax Act, 1961) and deferred tax charge or credit (reflecting the tax effect of timing differences between accounting income and taxable income for the period)

Deferred Tax:

Deferred tax is recognized, subject to the consideration of prudence, on timing differences, being the difference between taxable incomes and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax assets are not recognized on unabsorbed depreciation and carry forward of losses unless there is virtual certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

Earnings per share:

The basic earnings per share ('EPS') is computed by dividing the net profit after tax for the period attributable to equity shareholders by weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit after tax for the period attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares. The dilutive potential equity shares are deemed to be converted as of the beginning of the year, unless they have been issued at a later date.

2. (A) Earnings Per Share

Earnings Per Share	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Profit/(Loss) considered for computation of EPS		
Shares:	(76,798)	(54,598)
Number of equity shares at the beginning of period		
Add: Shares issued during the year	2,50,000	2,50,000
Total number of equity shares outstanding	21,61,000	-
Weighted Average number of equity shares	24,11,000	2,50,000
Basic Earning Per Share (EPS)	(3.19)	(21.84)
Profit/(Loss) considered for computation of DPS		
Shares:	(76,798)	(54,59,846)
Number of equity shares at the beginning of period		
Add: Shares issued during the year	2,50,000	2,50,000
Total number of equity shares outstanding	24,11,000	2,50,000

DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024

Weighted Average number of equity shares		
Number of Non-Cumulative CCPS at the beginning of period	20,50,833	2,50,000
Add: Shares issued during the year	-	16,78,800
Total number of CCPS outstanding	-	-
Diluted Earning Per Share (DPS)	(4)	(2.83)

2. (B) Deferred Tax Asset/(Liability) (Net)

	Year Ended March 31st, 2024	Year Ended March 31st, 2023
A. Deferred Tax Liability	-	-
B. Deferred Tax Asset	35,795	35,844
Net Deferred Tax Asset/(Deferred Tax Liability)	35,795	35,844

2(C) Related Party Disclosure (AS 18)
(a) Name of the related parties and nature of relationship (as per AS 18)

Name of Related Party	Nature of Relationship
Anand Kumar Bhashyakarla	Director
Milind Ravi	Director
Soham Satish Modi	Director

(b) Transactions with Related Parties

Name of Related Party	Nature	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Anand Kumar Bhashyakarla	Loan Repayment	31,053	1,385
JVRX Asset Management Pvt Ltd	Interest Payable	6,064	5,890
JVRX Asset Management Pvt Ltd	Loan Repayment	24,110	-
JVRX Asset Management Pvt Ltd	Issued Equity Shares	24,110	-
Kalluri Venkata Nagabushnam	Loan Taken	40,000	92,447
Kalluri Venkata Narasimha Murthy	Loan Taken	15,000	1,67,447
Modi Properties Pvt Ltd	Loan Taken	2,84,970	1,06,900
Modi Properties Pvt Ltd	Loan Repayment	69,250	18,108
Modi Properties Pvt Ltd	Interest Payable	24,073	-
Modi Properties Pvt Ltd	Issued Equity Shares	24,110	-
Nareddy Kiran Kumar Reddy	Loan Taken	20,000	1,17,447
Naredla Krishnaveni	Loan Taken	70,000	57,447
Vijaya Bhaskar Reddy	Unsecured Loan	10,000	1,12,448
Modi Constructions & Realtors LLP	Loans & Advances (Assets)	71,883	5,250
Modi Constructions & Realtors LLP	Loans & Advances (Assets)	20,100	2,92,757
Summit Builders	Loan Taken	-	577
Summit Builders	Service Provider	-	1,062

(c) Related Parties Balances

Name of Related Party	Nature of Relationship	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Anand Kumar Bhashyakarla	Unsecured Loan	2,31,250	2,62,303
JVRX Asset Management Pvt Ltd	Unsecured Loan	66,511	95,922
Kalluri Venkata Nagabushnam	Unsecured Loan	2,31,250	1,91,250
Kalluri Venkata Narasimha Murthy	Unsecured Loan	2,31,250	2,16,250
Modi Properties Pvt Ltd	Unsecured Loan	5,12,422	3,20,813
Nareddy Kiran Kumar Reddy	Unsecured Loan	2,31,250	2,11,250
Naredla Krishnaveni	Unsecured Loan	1,76,250	1,06,250
Vijaya Bhaskar Reddy	Unsecured Loan	2,31,251	2,21,251
Modi Properties Pvt Ltd	Capital Account	60,27,500	4,68,750
Modi Constructions & Realtors LLP	Loans & Advances (Assets)	20,24,578	72,02,896

2(D) Previous years' figures have been regrouped/ reclassified wherever necessary in the current year's grouping/ classification.

2(E) No transactions to report against the following:

- Crypto Currency or Virtual Currency.
- Benami Property held under Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- Registration of charges or satisfaction with Registrar of Companies.
- Relating to borrowed funds:
 - Willful defaulter.
 - Utilisation of borrowed funds & share premium.
 - Borrowings obtained on the basis of security of current assets.
 - Discrepancy in utilisation of borrowings.

2 (F) The Company is currently in its pre-operative phase and is in the process of setting up its Bio-tech leasing facility. As at March 31, 2024, the Company has incurred substantial expenditure on Capital Work in Progress amounting to Rs. 28,55,307 which is reflected under Non-Current Assets. These expenditures primarily comprise major components like construction costs, pre-operative expenses etc. Due to the pre-operative nature of activities and absence of commercial operations, the Company has accumulated losses resulting in negative net assets of Rs. 54,259 (amount in hundreds). The management is confident of commencing commercial operations by 31st December, 2025 and has secured necessary funding commitments from Promoters and Financers to meet the project completion costs and working capital requirements. Accordingly, these financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.



2

DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in INR unless otherwise stated)

2(E) Ratios

SL No	Particulars	Numerator	Denominator	March 31, 2024	March 31, 2023	Variance	Reason for Variance
(i)	Current Ratio	Current assets	Current liabilities	1.56	3.63	0.57	Company has obliged to pay loan installements which is to be accrued during the assesment year.
(ii)	Debt-Equity Ratio	Total Debt	Shareholder's Equity	-60.90	-96.73	0.37	CCPS some Other loans converted into Equity shares.
(iii)	Debt Service Coverage Ratio	Earnings available for debt service	Debt Service	NA	NA	NA	The company has not started its operations till 31.03.2024
(iv)	Return on Equity (ROE)	Net Profits after taxes	Average Shareholder's Equity	NA	NA	NA	The company has not started its operations till 31.03.2024
(v)	Inventory turnover ratio	Cost of Goods Sold	Average Inventory	NA	NA	NA	The company has not started its operations till 31.03.2024
(vi)	Trade Receivable turnover ratio	Revenue	Average Trade Receivable	NA	NA	NA	The company has not started its operations till 31.03.2024
(vii)	Trade payables turnover ratio	Purchases of services and other expenses	Average Trade Payables	NA	NA	NA	The company has not started its operations till 31.03.2024
(viii)	Net Capital Turnover Ratio	Revenue	Working Capital	NA	NA	NA	The company has not started its operations till 31.03.2024
(ix)	Net profit ratio	Net Profit	Revenue	NA	NA	NA	The company has not started its operations till 31.03.2024
(x)	Return on capital employed (ROCE)	Earning before interest and taxes	Capital Employed	NA	NA	NA	The company has not started its operations till 31.03.2024
(xi)	Return on Investment(ROI)	Income generated from investments	Time weighted Average Investments	NA	NA	NA	The company has not started its operations till 31.03.2024

As per out report of even date
for Laxminivas & Co.
Chartered Accountants
Firm Registration No. 011168S



Vijay Singh
Partner

Membership No. 221671
UDIN: **24221671BKBMQZ7852**
Place : Hyderabad
Date : **02.09.2024**

For and on behalf of directors of
Dr. N.R.K. Bio-Tech Private Limited
CIN: U45100TG2004PTC044950



Soham Satish Modi
Director
DIN: 00522546


Anand Kumar Bhashyarkarla
Director
DIN: 07739186

DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)

3 Share Capital

Particulars	As at March 31st, 2024	As at March 31st, 2023
Authorized Capital		
Equity Share Capital		
50,00,000 number of equity shares of Rs. 10 each	5,00,000	50,000
Preference Share Capital		
20,00,000 number of preference shares of Rs. 10 each	-	2,00,000
Total	5,00,000	2,50,000
Issued, Subscribed and Paid-up Capital		
Equity Share Capital		
24,11,000 number of equity shares of Rs. 10 each fully paid up	2,41,100	25,000
Preference Share Capital		
16,78,800 number of equity shares of Rs. 10 each fully paid up	-	1,67,880
Total	2,41,100	1,92,880

(a) Equity Share Capital

(i) Reconciliation of Number of Equity Shares

Particulars	As at March 31st, 2024		As at March 31st, 2023	
	Number	Amount	Number	Amount
Issued, Subscribed and Paid-up Capital				
Outstanding shares at the beginning of the year	24,11,000	2,41,10,000	2,50,000	25,00,000
Shares Issued during the year	-	-	-	-
Share bought back during the year	-	-	-	-
Outstanding Shares at the end of the year	24,11,000	2,41,10,000	2,50,000	25,00,000

(ii) Details of Shareholders holding more than 5% of equity shares during the year

Particulars	As at March 31st, 2024		As at March 31st, 2023	
	Number	Percentage %	Number	Percentage %
B Anand Kumar	2,41,100	10.00%	31,250	12.50%
JVRX Asset Management Pvt Ltd	3,61,650	15.00%	15,625	6.25%
K Venkata Nagabhushnam	2,41,100	10.00%	31,250	12.50%
K Venkata Narsimha Murty	2,41,100	10.00%	31,250	12.50%
K Vijay Bhaskar	2,41,100	10.00%	31,250	12.50%
Modi Properties Pvt Ltd	6,02,750	25.00%	46,875	18.75%
N Kiran Kumar	2,41,100	10.00%	31,250	12.50%
N Krishna Veni	2,41,100	10.00%	31,250	12.50%
Total	24,11,000	100.00%	2,50,000	100.00%

(iii) Rights, preference and restrictions attached to Equity Shares

The Company has only one class of equity shares having a par value of ₹ 10 each per share. Each holder of equity shares is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to the approval of the Shareholders in the ensuing Annual General Meeting. **Note:** No dividends has been paid to Preference shareholders during the year. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts if any. The distribution will be in proportion to number of equity shares held by the shareholders.




(b) Preference Shares Capital

(i) Reconciliation of Number of Preference Shares

Particulars	As at March 31st, 2024		As at March 31st, 2023	
	Number	Amount	Number	Amount
Issued, Subscribed and Paid-up Capital				
Outstanding shares at the beginning of the year	-	-	16,788	1,67,880
Shares Issued during the year	-	-	-	-
Share bought back during the year	-	-	-	-
Outstanding Shares at the end of the year	-	-	16,788	1,67,880

(ii) Details of Shareholders holding more than 5% of preference shares during the year

Particulars	As at March 31st, 2024		As at March 31st, 2023	
	Number	Percentage %	Number	Percentage %
B Anand Kumar	-	0.00%	2,09,850	12.50%
JVRX Asset Management Pvt Ltd	-	0.00%	1,04,925	6.25%
K Venkata Nagabhushnam	-	0.00%	2,09,850	12.50%
K Venkata Narsimha Murty	-	0.00%	2,09,850	12.50%
K Vijay Bhaskar	-	0.00%	2,09,850	12.50%
Modi Properties Pvt Ltd	-	0.00%	3,14,775	18.75%
N Kiran Kumar	-	0.00%	2,09,850	12.50%
N Krishna Veni	-	0.00%	2,09,850	12.50%
Total	-	0.00%	16,78,800	100.00%

4 Reserves and Surplus

Particulars	As at	As at
	March 31st, 2024	March 31st, 2023
Securities Premium Account		
Opening Balance		
Add: Profit/(Loss) for the year	80,500	80,500
Closing Balance	80,500	80,500
Surplus/(Deficit) in Statement of Profit and Loss		
Opening Balance		
Add: Profit/(Loss) for the year	(2,99,015)	(2,44,417)
Closing Balance	(76,847)	(54,598)
Total	(2,95,359)	(2,18,515)







DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)

5a Long-term Borrowings

Particulars	As at March 31st, 2024	As at March 31st, 2023
Secured:		
Loan from Banks (Refer note (i) below)	-	-
Loan from Others (Refer note (i) below)	13,68,154	8,54,450
Unsecured:		
Loan from Banks (Refer note (i) below)	-	-
Loan from Others (Refer note (i) below)	19,36,434	16,25,288
Total	33,04,588	24,79,738

5b Short-term Borrowings

Particulars	As at March 31st, 2024	As at March 31st, 2023
Secured:		
Loan from Banks (Refer note (i) below)	76,050	-
Loan from Others (Refer note (i) below)	-	-
Unsecured:		
Loan from Banks (Refer note (i) below)	-	-
Loan from Others (Refer note (i) below)	-	-
Total	76,050	-

(i) Borrowing reported above includes:

Particulars	As at March 31st, 2024	As at March 31st, 2023
Secured:		
Bonds/Debentures	-	-
Term Loans	-	-
from Banks	-	-
from Others	-	-
Deferred payment liabilities	-	-
Deposits	-	-
Loans and advances from related parties	-	-
Long term maturities of finance lease obligations	-	-
Other loans and advances	-	-
Vehicle Loan	-	4,450
Other Loans	14,44,203	8,50,000
Unsecured:		
Bonds/Debentures	-	-
Term Loans	-	-
from Banks	-	-
from Others	-	-
Deferred payment liabilities	-	-
Deposits	-	-
Loans and advances from related parties	-	-
Long term maturities of finance lease obligations	8,35,183	6,79,037
Other loans and advances	-	-
	11,01,251	9,46,251
Total	33,80,637	24,79,738





DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)

6 Trade Payables

Particulars	As at March 31st, 2024	As at March 31st, 2023
Sundry Creditors		
-Due to Micro, Small and Medium Enterprise*	-	-
-Due to Others	1,42,178	1,25,184
Total	1,42,178.26	1,25,184.42

* The company does not have any information relating to amounts payable to Micro, Small and Medium Enterprise as on March 31, 2024

Note 6.1 Trade Payables Ageing Schedule

Trade Payable ageing schedule as on 31st March, 2024

PARTICULARS	Outstanding for the following periods from the due date of payment						
	As at 31st March 2024	Not due	Less than 1 year	1-2 years	2-3 Years	More than 3 Years	Total
(i) Dues to MSME		-	-	-	-	-	-
(ii) Dues to Others		-	1,42,17,826	-	-	-	1,42,17,826
(iii) Disputed dues to MSME		-	-	-	-	-	-
(iv) Disputed dues to Others		-	-	-	-	-	-
GRAND TOTAL		-	1,42,17,826	-	-	-	1,42,17,826

Trade Payable ageing schedule as on 31st March, 2023

PARTICULARS		Outstanding for the following periods from the due date of payment					
As at 31st March 2022		Not due	Less than 1 year	1-2 years	2-3 Years	More than 3 Years	Total
(i)	Dues to MSME	-	-	-	-	-	-
(ii)	Dues to Others	-	1,25,184	-	-	-	1,25,184
(iii)	Disputed dues to MSME	-	-	-	-	-	-
(iv)	Disputed dues to Others	-	-	-	-	-	-
GRAND TOTAL		-	1,25,184	-	-	-	1,25,184

(2)

(Signature)

(Signature)


DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)

7 Other Current Liabilities

Particulars	As at March 31st, 2024	As at March 31st, 2023
TDS Payable	7,670	4,630
GST Payable	328	328
Professional Tax Payable	8	8
Deposits	10,000	-
Interest payable	32,429	-
Other payable	145	-
Total	50,578	5,280

8 Short Term Provision

Particulars	As at March 31st, 2024	As at March 31st, 2023
Provision for Audit Fees	350	350
Provision for ITR Filing fees	60	-
- TDS @ 10%	(41)	(35)
Total	369	315



9A Property, Plant & Equipment (Current Year, FY 2023-24)

Particulars	Gross Block				Depreciation				Net Block	
	As at April 1st, 2023	Additions	Adjustments	As at March 31st, 2024	As at April 1st, 2023	For the year	Adjustments	As at March 31st, 2024	As at March 31st, 2023	As at March 31st, 2023
Tangible:										
Land	1,58,425	-	-	1,58,425	-	-	-	-	1,58,425	1,58,425
Buildings	80,420	1,918	-	80,420	31,314	2,547	-	33,860	45,560	49,107
Motor Vehicle	8,981	299	3,900	6,999	1,003	901	(2,234)	4,138	2,861	7,978
Computers & Peripherals	-	-	-	-	-	53	-	53	-	-
Total	2,47,826	2,217	3,900	2,46,144	32,317	3,500	(2,234)	36,051	2,06,093	2,15,509

9A Property, Plant & Equipment (Current Year, FY 2022-23)

Particulars	Gross Block				Depreciation				Net Block	
	As at April 1st, 2022	Additions	Adjustments	As at March 31st, 2023	As at April 1st, 2022	For the year	Adjustments	As at March 31st, 2023	As at March 31st, 2022	As at March 31st, 2022
Tangible:										
Land	1,58,425	-	-	1,58,425	-	-	-	-	1,58,425	1,58,425
Buildings	80,420	-	-	80,420	25,282	6,032	-	31,314	49,107	55,138
Motor Vehicle	4,397	4,584	-	8,981	330	674	-	1,003	7,978	4,067
Total	2,43,242	4,584	-	2,47,826	25,612	6,705	-	32,317	2,15,509	2,17,630

9B Capital Work In Progress (Current Year, FY 2023-24)

Particulars	Gross Block				Depreciation				Net Block	
	As at April 1st, 2023	Additions	Adjustments	As at March 31st, 2024	As at April 1st, 2023	For the year	Adjustments	As at March 31st, 2024	As at March 31st, 2023	As at March 31st, 2023
Building under construction	18,60,125	9,95,182	-	28,55,307	-	-	-	-	28,55,307	18,60,125
Total	18,60,125	9,95,182	-	28,55,307	-	-	-	-	28,55,307	18,60,125

9B Capital Work In Progress (Current Year, FY 2022-23)

Particulars	Gross Block				Depreciation				Net Block	
	As at April 1st, 2022	Additions	Adjustments	As at March 31st, 2023	As at April 1st, 2022	For the year	Adjustments	As at March 31st, 2023	As at March 31st, 2022	As at March 31st, 2022
Building under construction	6,99,563	11,60,562	-	18,60,125	-	-	-	-	18,60,125	6,99,563
Total	6,99,563	11,60,562	-	18,60,125	-	-	-	-	18,60,125	6,99,563

CWIP Ageing Schedule - 31st March 2024

Particulars	Amount in CWIP for a period of					Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years		
Project in progress	9,95,182	11,60,562	4,23,344	2,76,218	28,55,307	
Total	9,95,182	11,60,562	4,23,344	2,76,218	28,55,307	

CWIP Ageing Schedule - 31st March 2023

Particulars	Amount in CWIP for a period of					Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years		
Project in progress	11,60,562	4,23,344	-	2,76,218	18,60,125	
Total	11,60,562	4,23,344	-	2,76,218	18,60,125	

(Handwritten signatures and initials)

DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)



10 Deferred Tax Assets

Particulars	As at March 31st, 2024	As at March 31st, 2023
Deferred tax asset	35,795	35,844
Total	35,795	35,844

11 Cash and Cash Equivalents

Particulars	As at March 31st, 2024	As at March 31st, 2023
Cash-in-hand	1,207	4,183
Balance with Bank:		
In Term Deposits account		
In Current account	6,077	40,079
Yes Bank	1,328	12,400
Total	8,613	56,663

(39) ✓

✓

DR. N.R.K. BIO-TECH PRIVATE LIMITED
NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024
(All amounts in Rs. hundreds, unless otherwise stated)

12 Loans and Advances

Particulars	As at March 31st, 2024	As at March 31st, 2023
Secured:		
Loans and Advances to Related Party	3,000	1,000
Loans and Advances to Others	85,840	76,840
Unsecured:		
Loans and Advances to Related Party	20,246	73,037
Loans and Advances to Others	5,729	47,581
Total	1,14,815	1,98,458

(i) Borrowing reported above includes:

Particulars	As at March 31st, 2024	As at March 31st, 2023
Secured:		
Bonds/Debentures	-	-
Loans and advances to Related Parties	-	-
Deposits*	3,000	1,000
Loans and advances	-	-
Other loans and advances	-	-
Deposits*	63,000	31,000
Loans and advances to suppliers	22,369	11,039
Others	471	34,801
Unsecured:		
Bonds/Debentures	-	-
Loans and advances to Related Parties	-	-
Deposits	-	-
Loans and advances	20,246	73,037
Other loans and advances	-	-
Deposits	-	-
Loans and advances to suppliers	-	-
Others	-	-
Total	1,14,815	1,98,458

* Note: Secured loans and advances includes deposits

13 Other Current Assets

Particulars	As at March 31st, 2024	As at March 31st, 2023
Balance with Revenue Authorities	2,96,404	2,17,970
TDS Receivable 23-24	476.07	
Total	2,96,880	2,17,970







DR. N.R.K. BIO-TECH PRIVATE LIMITED**NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2024**

(All amounts in Rs. hundreds, unless otherwise stated)

14 Revenue from Operations

Particulars	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Sale of Goods		
Total	-	347
	-	347

15 Other Income

Particulars	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Interest on Fixed Deposit		
Miscellaneous Income	4,761	5,050
Interest on Income tax refund	262	-
Total	30	-
	5,052	5,050

16 Employee Benefit Expenses

Particulars	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Salary, wages, other remuneration		
Staff Welfare Expenses	7,346	5,849
Total	4	8
	7,350	5,858

17 Finance Cost

Particulars	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Bank Charges		
Total	28	25
	28	25

18 Other Administrative Expenses

Particulars	Year Ended March 31st, 2024	Year Ended March 31st, 2023
Audit fee		
Consultancy Charges	410	350
Legal Services	13,050	28,197
Written Off	-	75
Admin Service Charges	719	-
Carhire Charges	7,015	4,700
Staff - Comm. & Logistics 18%	1,683	1,501
Maintenance Charges	-	4,359
ROC Charges	39,184	3,876
GST Late Fees	2,250	324
Interest on TDS	7	127
Other miscellaneous expenses	506	633
Park Maintenance Charges	2,739	1,400
Printing & Stationery	-	-
Advertisement & Promotion Expenses	847	1,112
Loss on sale of Car	328	190
Total	2,234	-
	70,971	46,843





INDEPENDENT AUDITOR'S REPORT

To The Members of DR. N.R.K BIO-TECH PRIVATE LIMITED

Report on Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **DR. N.R.K BIO-TECH PRIVATE LIMITED** (the 'Company'), which comprise the balance sheet as at 31st March 2024, the statement of profit and loss for the year then ended and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information (herein after referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Accounting Standards specified under Section 133 of the Act, of the state of affairs of the company as at 31st March 2024, its loss for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements Section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 4 in the financial statements, which indicates that the Company incurred a net loss of Rs. 76,847 (amount in hundreds) during the year ended March 31, 2024. The management is confident of commencing commercial operations by 31st December, 2025 and has secured necessary funding commitments from Promoters and Financers to meet the project completion costs and working capital requirements. As stated in Note 1-2 these events or conditions, along with other matters as set forth in Note 1-2, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Responsibilities of Management for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021.



T: 040 2324 0700
040 2324 0900



www.Lncofirm.in



Laxminiwas & Co.

Head Office: 6-3-569, 4th Floor, Above BMW Showroom,
Opp. RTA Office Khairatabad, Hyderabad 500082, Telangana, India.

The responsibility also includes maintenance of the adequate accounting records for safeguarding assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the management of the company is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The management and Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for Audit of Financial Statements:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

1. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial



statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Materiality is the magnitude of misstatement in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatement in the standalone financial statements.

We communicate with the Board of Directors, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Board of Directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. This report does not include a statement on the matters specified in Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, since in our opinion and according to the information and explanation given to us, the said Order is not applicable to the company.
2. Clause (i) of section 143 (3) is not applicable pursuant to notification G.S.R 583(E) dated 13 June 2017.
3. As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet and the Statement of Profit and Loss dealt with by this report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid financial statements comply with the Accounting standards specified under Section 133 of the Companies Act, 2013.



- (e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2023 from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- (i) There are no pending litigations on or by the company, the impact of which needs to be disclosed in financial statement.
 - (ii) The Company does not have any long-term contracts, including derivative contracts, for which there were any material foreseeable losses; and
 - (iii) There are no amounts which were required to be transferred to the Investor Education and Protection Fund during the year ended 31st March 2024.
 - (iv)
 - a. The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether,
 - a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or
 - b. provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - b. The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether,
 - a. directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or
 - b. provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - c. Based on our audit procedures, we have considered it reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause iv(a) and iv(b) contain any material misstatement.
 - (v) The company has not declared or paid any dividend during the year.



- (g) With respect to the matter to be included in the Auditor's Report under section 197(16) of the Act, in our opinion, and according to the information and explanations given to us, and based on our examination of the records of the company, the provisions of section 197 read with Schedule V of the Act are not applicable to the Company as it a private limited company.
- (h) Based on our examination which included test check the company have used an accounting software for maintaining its books of account which has a feature of recording audit trail (Edit log) facility and the same has operated throughout the year for all relevant transaction recorded in the software. For the, during the course of our audit, we did not come across any instance in audit trail feature being tampered with. Additionally, the Audit trail has been preserved by the company as per the statutory requirements for record retention.

For LAXMINIWAS & CO.

Chartered Accountants

Firm's Registration Number: 011168S



VIJAY SINGH

Partner

Membership Number: 221671



Place: Hyderabad

Date: 3rd September, 2024

UDIN: **24221671BKBMQZ7852**